论文部分内容阅读
目的研究吲达帕胺对雌性和雄性大鼠替米沙坦药代动力学的影响。方法Wistar大鼠随机分为替米沙坦单用和替米沙坦与吲哒帕胺联用组,雌雄各半,分别单次ig给予替米沙坦3.6mg·kg-1或替米沙坦3.6mg·kg-1+吲达帕胺0.135mg·kg-1。96h内定时取血后,采用反相高效液相色谱-荧光检测法测定血浆中替米沙坦浓度。结果无论雄性雌性大鼠,与替米沙坦单用组相比,联用吲达帕胺后替米沙坦的主要药代动力学参数无显著性改变;而不同性别大鼠替米沙坦的药代动力学有显著差异,无论替米沙坦单用或联用吲达帕胺组,雌性大鼠替米沙坦的主要药代动力学参数AUC和cmax值均显著高于雄性,而血浆清除率显著低于雄性。结论替米沙坦与吲达帕胺联用对大鼠替米沙坦的药代动力学无明显影响;而无论替米沙坦单用或联用吲达帕胺,雌性和雄性大鼠替米沙坦的药代动力学存在显著的性别差异。
Objective To investigate the effects of indapamide on the pharmacokinetics of telmisartan in female and male rats. Methods Wistar rats were randomly divided into telmisartan alone and telmisartan combined with indapamide group, male and female, respectively, a single ig given telmisartan 3.6 mg · kg-1 or telmisartan Tamsulosin 3.6 mg · kg-1 + indapamide 0.135mg · kg-1.96h within the given time after taking blood, using reverse-phase high performance liquid chromatography - fluorescence detection of plasma concentrations of telmisartan. RESULTS: In male rats, the main pharmacokinetic parameters of telmisartan were not significantly changed in comparison with telmisartan alone; telmisartan The pharmacokinetics of telmisartan was significantly higher than that of male, no matter telmisartan alone or in combination with indapamide group, the main pharmacokinetic parameters AUC and cmax of telmisartan in female rats were significantly higher than those in male Plasma clearance was significantly lower than that of males. Conclusion The combination of telmisartan and indapamide had no significant effect on the pharmacokinetics of telmisartan in rats. Whether telmisartan alone or in combination with indapamide, female and male rats There is a significant gender difference in the pharmacokinetics of lisartan.